Exposure of hIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitness

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 582-593

  Mathys, Leen ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

CBAs; Envelope gp120; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LECTIN; MONOCLONAL ANTIBODY; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL RESISTANCE; CARBOHYDRATE METABOLISM; DNA SEQUENCE; DRUG EFFECTS; GENETIC SELECTION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; VIRULENCE;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; CARBOHYDRATE METABOLISM; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; LECTINS; PROTEIN BINDING; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; VIRULENCE;

EID: 84894085065     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt414     Document Type: Article

References (29)

1. Bonomelli C, Doores KJ, Dunlop DC et al. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 2011; 6: e23521.
2. Pollack L, Atkinson PH. Correlation of glycosylation forms with position in amino acid sequence. J Cell Biol 1983; 97: 293-300.
3. Wang LX, Ni J, Singh S et al.Bindingofhigh-mannose-typeoligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. ChemBiol 2004; 11: 127-34.
4. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 2007; 5: 583-97.
5. Petrova MI, Mathys L, Lebeer S et al. Inhibition of infection and transmission of HIV-1 and lack of significant impact on the vaginal commensal lactobacilli by carbohydrate-binding agents. J Antimicrob Chemother 2013; 68: 2026-37.
6. Balzarini J, Van Herrewege Y, Vermeire K et al. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 2007; 71: 3-11.
7. Feinberg H, Mitchell DA, Drickamer K et al. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001; 294: 2163-6.
8. Kaku H, Van Damme EJ, Peumans WJ et al. Carbohydrate-binding specificity of the daffodil (Narcissus pseudonarcissus) and amaryllis (Hippeastrumhybr.) bulb lectins. Arch BiochemBiophys 1990; 279: 298-304.
9. Hoorelbeke B, vanMonfort T, Xue J et al. HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120. FEBS Lett 2013; 587: 860-6.
10. Balzarini J, Van LK, Hatse S et al. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 2004; 78: 10617-27.
11. Balzarini J, Hatse S, Vermeire K et al. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 2004; 48: 3858-70.
12. Calarese DA, Scanlan CN, Zwick MB et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300: 2065-71.
13. Sanders RW, Venturi M, Schiffner L et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76: 7293-305.
14. Scanlan CN, Pantophlet R, Wormald MR et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of a1→2 mannose residues on the outer face of gp120. J Virol 2002; 76: 7306-21.
15. Trkola A, Purtscher M, Muster T et al. Humanmonoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70: 1100-8.
16. Huskens D, Van Laethem K, Vermeire K et al. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 2007; 360: 294-304.
17. Manrique A, Rusert P, Joos B et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007; 81: 8793-808.
18. Férir G, Huskens D, Palmer KEet al. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV type 1 strains. AIDS Res Hum Retroviruses 2012; 28: 1513-23.
19. Princen K, Hatse S, Vermeire K et al. Establishment of a novel CCR5 and CXCR4 expressing CD4+cell line which is highly sensitive to HIVand suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 2004; 1: 2.
20. Weber J, Weberova J, Carobene M et al. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 2006; 136: 102-17.
21. Van Laethem K, Schrooten Y, Lemey Pet al. Agenotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 2005; 123: 25-34.
22. Abacioglu YH, Fouts TR, Laman JD et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 1994; 10: 371-81.
23. Leonard CK, Spellman MW, Riddle L et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990; 265: 10373-82.
24. Férir G, Vermeire K, Huskens D et al. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Res 2011; 90: 200-4.
25. Auwerx J, Francois KO, Covens K et al. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 2008; 382: 10-9.
26. Huskens D, Ferir G, Vermeire K et al. Microvirin, a novel a(1,2)- mannose-specific lectin isolated from Microcystis aeruginosa, has anti- HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem2010; 285: 24845-54.
27. Balzarini J, Van Laethem K, Daelemans D et al. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. J Virol 2007; 81: 362-73.
28. Balzarini J,VanLaethemK,HatseS et al.Carbohydrate-bindingagents cause deletionsofhighlyconservedglycosylation sites inHIVGP120:anewtherapeutic concept to hit the Achilles heel of HIV. J Biol Chem2005; 280: 41005-14.
29. Balzarini J, Van Laethem K, Hatse S et al. Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. Mol Pharmacol 2005; 67: 1556-65.